Navigation Links
Reportlinker Adds Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development
Date:4/28/2011

NEW YORK, April 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development

http://www.reportlinker.com/p0487115/Case-Study-Personalized-Cancer-Therapy---The-era-of-biomarker-identification-and-companion-diagnostic-co-development.html

Introduction

The treatment of cancer has seen a dramatic shift with the addition of molecular targeted therapies. The mixed and unpredictable responses to these targeted therapies are driving the pharmaceutical industry to search for disease and patient characteristics which confer the best response rates. Identification of biomarkers and companion diagnostics will pave the way for personalized cancer therapy.

Scope of this research

• In-depth analysis of companion diagnostic development – when to start development, internal or partnership development, with case study examples

• In-depth analysis of personalized cancer therapy commercial potential – with patient population analysis and case studies

• In-depth analysis of US, EU, and Japanese current and developing regulatory processes for personalized cancer therapy

• Sales forecasts for two key personalized therapies in late stage development - 2010 to 2019 across the seven major markets

Research and analysis Highlights

Pharmaceutical companies face a number of important decisions regarding personalized therapy development. Selecting the correct time to begin companion diagnostic development will help improve the chances of approval and drive new drug uptake. Developers must also assess their position in the market before choosing internal or external development.

Drug developers are cautious of personalized therapies due to the small patient populations and associated commercial potential. However, Herceptin has been able to dominate a well defined segment of the breast cancer market and companion diagnostics have recovered the commercial potential of Erbitux and Vectibix.

Regulators have now realized that the regulatory framework must be altered to incorporate both drugs and companion diagnostics. The US, EU and Japanese authorities are all starting to change their guidelines to encourage personalized therapy development. However, there are still hurdles to overcome before co-development becomes common practice.

Key

Reasons to Purchase this research

• Identify key decisions when developing a drug and companion diagnostic, including internal or external development and when to start development

• Identify the commercial benefits of personalized cancer therapy by assessing drugs currently in development or approved

• Assess the changes in regulatory processes in the seven major markets as the paradigm of personalized cancer medicine grows

TABLE OF CONTENTS

Overview 1

Catalyst 1

Summary 1

About Datamonitor Healthcare 2

About the oncology pharmaceutical analysis team 2

Executive Summary 3

Strategic scoping and focus 3

Datamonitor key findings 3

Related reports 4

Case Study in Personalized Cancer Therapy 6

Introduction 6

Biomarkers 7

Drug and companion diagnostic development 12

Commercial potential 18

Regulators 22

Key pipeline personalized cancer therapies 28

Bibliography 35

Introduction 35

Biomarkers 36

Drug and companion diagnostic development 36

Commercial potential 39

Regulators 41

Key pipeline personalized cancer therapies 42

Appendix A 44

Forecasting assumptions 44

Appendix B 45

Report methodology 45

About Datamonitor 45

To order this report:

: Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds Infectious Disease Molecular Diagnostic Testing
2. Reportlinker Adds Smart Glass: Technologies and Global Markets Report
3. Reportlinker Adds Synthetic Biology: Emerging Global Markets Report
4. Reportlinker Adds Proteomics: Technologies and Global Markets Report
5. Reportlinker Adds Nanomedicine Report
6. Reportlinker Adds Small Molecule Kinase Inhibitors Report
7. Reportlinker Adds Nanoporous Materials Report
8. Reportlinker Adds Membrane Bioreactors Report
9. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
10. Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report
11. Reportlinker Adds In Vitro Diagnostics in a Recession: IVD Market Forecasts, Analysis and Success Strategies Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... N.J. , Dec. 5, 2016  Eisai ... 3 open-label two-year study of rufinamide, which were ... American Epilepsy Society (AES) held from December 2-6 ... of final two-year safety, tolerability and cognitive data ... rufinamide experienced similar safety and tolerability profiles, cognitive ...
(Date:12/4/2016)... ... December 03, 2016 , ... Microbial genomics ... impact grant award has been made to Dr. Renato Polimanti of Yale University ... on the oral microbiome. Grant proposals have been vetted by the company’s scientific ...
(Date:12/2/2016)... COLD SPRING HARBOR, N.Y. , Dec. 2, 2016 /PRNewswire/ ... Spring Harbor Laboratory,s (CSHL) 11th Double Helix Medals dinner ( DHMD ). ... History (AMNH) in New York City ... Vagelos for their contributions, respectively, to health and medicine ... honored Muhammad Ali in 2006, the event has ...
(Date:12/2/2016)... , Dec 2, 2016 Research ... report "Nanobiotechnology Applications, Markets and Companies" to their ... , , ... nanobiotechnology by the pharmaceutical and biotechnology industries is anticipated. Nanotechnology ... from formulations for optimal delivery to diagnostic applications in clinical ...
Breaking Biology Technology:
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, Biometrics & ... & Other Service  The latest report from ... of the global Border Security market . Visiongain ... billion in 2016. Now: In November 2015 ... and hardware technologies for advanced video surveillance. ...
Breaking Biology News(10 mins):